Mimedx Group earnings were $40.2M for the trailing 12 months ending Mar 31, 2025, with -48.1% growth year over year. The latest MDXG earnings report on Mar 31, 2025 announced Q1 2025 earnings of $7.0M, down 5.6% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, MDXG reported annual earnings of $42.4M, with -27.2% growth.
MDXG past earnings growth
How has MDXG's earnings growth performed historically?
On MDXG's earnings call on Invalid Date, Mimedx Group (NASDAQ: MDXG) reported Q1 2025 earnings per share (EPS) of $0.05, up 16.67% year over year. Total MDXG earnings for the quarter were $7.02 million. In the same quarter last year, Mimedx Group's earnings per share (EPS) was $0.06.
As of the last Mimedx Group earnings report, Mimedx Group is currently profitable. Mimedx Group's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $40.18 million, a 44.56% decrease year over year.
What was MDXG's earnings growth in the past year?
As of Mimedx Group's earnings date in Invalid Date, Mimedx Group's earnings has grown -48.08% year over year. This is 72.2 percentage points lower than the US Biotechnology industry earnings growth rate of 24.12%. MDXG earnings in the past year totalled $40.18 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.